TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26712905

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (docetaxel 75 mg/m² day 1, cisplatin 75 mg/m² day 1, fluorouracil 300 mg/m²/day over days 1-14) before gastrectomy (arm A)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (docetaxel 75 mg/m² day 1, cisplatin 75 mg/m² day 1, fluorouracil 300 mg/m²/day over days 1-14) after gastrectomy (arm B)
Number of subjects: 70
Study: 24585161

Group type: EXPERIMENTAL
Intervention: Continuous bedside pressure mapping (CBPM) device
Number of subjects: 422

Group type: COMPARATOR
Intervention: Control group (without CBPM)
Number of subjects: 422
Study: 22883507

Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg
Number of subjects: 17603

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17603
Study: 20382638

Group type: EXPERIMENTAL
Intervention: Tuberculin Skin Test (TST)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tuberculin Skin Test (TST) for HIV-infected individuals
Number of subjects: 0
Study: 18097989

Group type: EXPERIMENTAL
Intervention: Cognitive enriched learning method (MH(2))
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard learning method (MH(1))
Number of subjects: 33

Group type: COMPARATOR
Intervention: Able-bodied (AB)
Number of subjects: 33
Study: 15613622

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 12065268

Group type: EXPERIMENTAL
Intervention: SHARE programme (intervention group)
Number of subjects: 8430

Group type: COMPARATOR
Intervention: Existing sex education (control programme)
Number of subjects: 8430
Study: 9661555

Group type: EXPERIMENTAL
Intervention: Epidural ketamine 60 mg administered before induction of anesthesia (Group 1)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Epidural ketamine 60 mg administered after the parietal peritoneum was closed (Group 2)
Number of subjects: 98
Study: 8123485

Group type: EXPERIMENTAL
Intervention: rhGM-CSF
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (unprotected cycles)
Number of subjects: 13
Study: 2598905

Group type: EXPERIMENTAL
Intervention: 1 h nap taken at 0200 h
Number of subjects: 6

Group type: COMPARATOR
Intervention: 300 mg caffeine ingested at 2315 h
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 1103897

Group type: EXPERIMENTAL
Intervention: 15 mg AR-DF 26 (gliquidone) - oral application
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: i.v. application of AR-DF 26
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: oral application of AR-DF 26
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: i.v. and oral application of AR-DF 26
Number of subjects: 10
Study: 6927657

Group type: EXPERIMENTAL
Intervention: Extra prompt condition (color-coded laces)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No extra prompt condition (naturalistic shoe)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Follow-up procedure (choice between color prompt and position cue)
Number of subjects: 20
Study: 31283892

Group type: EXPERIMENTAL
Intervention: CPP-ACP dentifrice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination CPP-ACP-cranberry dentifrice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluoride control dentifrice
Number of subjects: 0
Study: 31404817

Group type: EXPERIMENTAL
Intervention: Short course of piano training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short course of videogame training
Number of subjects: 0

Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 0
Study: 28657699

Group type: EXPERIMENTAL
Intervention: Low abrasivity aluminum trioxide/STP dentifrice (RDA40)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Ultra‐low abrasivity dentifrice (5% STP only; RDA13)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Moderate abrasivity fluoride dentifrice (RDA80)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Higher abrasivity whitening dentifrice (RDA142)
Number of subjects: 95
Study: 25677596

Group type: EXPERIMENTAL
Intervention: Tenecteplase 0.1 mg/kg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Tenecteplase 0.25 mg/kg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Tenecteplase (both doses)
Number of subjects: 50
Study: 23395356

Group type: EXPERIMENTAL
Intervention: Multifocal add-on IOL group
Number of subjects: 34

Group type: COMPARATOR
Intervention: Multifocal PC IOL group
Number of subjects: 34
Study: 20642488

Group type: EXPERIMENTAL
Intervention: 800 mg i.v.-ibuprofen every 6 hours
Number of subjects: 319

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 319
Study: 19384673

Group type: EXPERIMENTAL
Intervention: Solifenacin flexible dosing (5-10 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tolterodine 4 mg sustained release (SR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (assumed to be comparable to no treatment)
Number of subjects: 0
Study: 17197286

Group type: EXPERIMENTAL
Intervention: Local injury to the endometrium prior to controlled ovarian stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no local injury)
Number of subjects: 0
Study: 15100637

Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation (home program of vestibular habituation head movement exercises)
Number of subjects: 0
Study: 11336584

Group type: EXPERIMENTAL
Intervention: Bismuth-based triple therapy (bismuth compound plus metronidazole, tetracycline or amoxycillin) for 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proton-pump inhibitor (PPI)-based triple therapy for 1 week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC)-based triple therapy (PPI or RBC plus any two of metronidazole, amoxycillin, and clarithromycin) for 1 week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RBC-triple therapy for resistant strains
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General treatment regimens
Number of subjects: 0
Study: 9609422

Group type: EXPERIMENTAL
Intervention: Intracorporeal laser lithotripsy (ILL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Extracorporeal shock wave lithotripsy (ESWL)
Number of subjects: 60
Study: 7819706

Group type: EXPERIMENTAL
Intervention: 2000 IU of hCG, injected subcutaneously on days 3, 6, 9, and 12 after transvaginal aspiration (TVA)
Number of subjects: 77

Group type: COMPARATOR
Intervention: 50 mg daily injections of intramuscular progesterone from days 2 to 14 after TVA
Number of subjects: 77
Study: 2891940

Group type: EXPERIMENTAL
Intervention: Oral mexiletine (10 mg/kg bodyweight daily)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31442495

Group type: EXPERIMENTAL
Intervention: 250-μg patch (epicutaneous immunotherapy for peanut allergy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 0
Study: 27668978

Group type: EXPERIMENTAL
Intervention: Ultrasound (US)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: US combined with MRI
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intra-observer agreement among 3 readers
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Inter-observer agreement among 3 readers
Number of subjects: 40
Study: 26802884

Group type: EXPERIMENTAL
Intervention: Endoscopic approach (closure of the perforation with endoclips and SEMS)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Surgical repair (hepaticojejunostomy, suture of the perforation or duodenal suture)
Number of subjects: 23
Study: 23179351

Group type: EXPERIMENTAL
Intervention: 300 mg/kg nickel chloride
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 600 mg/kg nickel chloride
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 900 mg/kg nickel chloride
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control diet (corn-soybean basal diet)
Number of subjects: 240
Study: 21647813

Group type: EXPERIMENTAL
Intervention: LAP-specific training
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: SIL-specific training
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: LAP technique
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: SIL-specific simulator training
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: SIL training using STR instruments
Number of subjects: 45
Study: 19637959

Group type: EXPERIMENTAL
Intervention: Routine replacement of peripheral intravenous catheters at 72-96 hours
Number of subjects: 316

Group type: COMPARATOR
Intervention: Clinical monitoring of peripheral intravenous catheters (replacement only on clinical indication)
Number of subjects: 316
Study: 16784946

Group type: EXPERIMENTAL
Intervention: Cranio-caudal direction (group A)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Caudo-cranial direction (group B)
Number of subjects: 203
Study: 15282457

Group type: EXPERIMENTAL
Intervention: Continuous infusion of protamine sulphate (25 mg/h for 6 hours)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 300
Study: 10325668

Group type: EXPERIMENTAL
Intervention: Granisetron (GR) 1 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Prochlorperazine (PCh) 10 mg
Number of subjects: 13
Study: 9156935

Group type: EXPERIMENTAL
Intervention: Chromatographic fraction ultrafiltrate of plasma (substances in the first peak)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dialysis
Number of subjects: 20
Study: 1680533

Group type: EXPERIMENTAL
Intervention: Azelastine (8 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketotifen (2 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6412508

Group type: EXPERIMENTAL
Intervention: Penicillin-V, 55 mg/kg/day for two days
Number of subjects: 103

Group type: COMPARATOR
Intervention: Penicillin-V, 55 mg/kg/day for seven days
Number of subjects: 103
Study: 31725362

Group type: EXPERIMENTAL
Intervention: Low-load blood flow restriction (LL-BFR) training (20-35% of one-repetition maximum)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: High-load (HL) resistance training (70-85% of one-repetition maximum)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Non-exercising control (CON) group
Number of subjects: 55
Study: 29389472

Group type: EXPERIMENTAL
Intervention: Acupuncture (ACU) therapy for 8 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 26998820

Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D (25(OH)D) levels
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Serum EBNA‐1 IgG levels
Number of subjects: 90
Study: 25114127

Group type: EXPERIMENTAL
Intervention: KAE609 (Cipargamin) 1 to 300 mg single dose
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: KAE609 (Cipargamin) 10 to 150 mg once daily for 3 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: KAE609 (Cipargamin) with high fat food intake
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: KAE609 (Cipargamin)
Number of subjects: 40
Study: 22212720

Group type: EXPERIMENTAL
Intervention: Timothy immunotherapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mite immunotherapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Overall assessment of conjunctival sensitivity
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Allergen-specific IgG
Number of subjects: 20
Study: 19059655

Group type: EXPERIMENTAL
Intervention: Stepwise elevated exercise intensity in volunteers
Number of subjects: 63

Group type: COMPARATOR
Intervention: DFA analysis in ACS patients
Number of subjects: 63
Study: 18302834

Group type: EXPERIMENTAL
Intervention: Azelastine (H(1)-antihistamine)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15747809

Group type: EXPERIMENTAL
Intervention: RME-Sz
Number of subjects: 44

Group type: COMPARATOR
Intervention: RME-only
Number of subjects: 44
Study: 12665084

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) plus contingency management (CM)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Contingency management (CM)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 193
Study: 10596569

Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy (ES)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Non-treated control group
Number of subjects: 104
Study: 9005798

Group type: EXPERIMENTAL
Intervention: Ofloxacin administered intravenously in a dose of 200 mg twice a day followed by oral use in the form of tablets in a dose of 200 mg twice a day for 5 to 6 days.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ofloxacin used orally in the form of tablets in a dose of 200 mg once a day in the morning for 5 to 7 days.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ofloxacin used in the same dosage but in combination with some other antibiotics.
Number of subjects: 25

Group type: COMPARATOR
Intervention: Antibiotics except for ofloxacin.
Number of subjects: 25
Study: 1752022

Group type: EXPERIMENTAL
Intervention: High tidal volume (HVT, 12.7 ml.kg‐1) ventilation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional tidal volume (CVT, 7.5 ml.kg‐1) ventilation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Manual hyperinflations (HI) of the lungs
Number of subjects: 24
Study: 6753115

Group type: EXPERIMENTAL
Intervention: Pirenzepine (100 mg/day for six weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30341408

Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 28991600

Group type: EXPERIMENTAL
Intervention: Reflective training during a 12-month clinical internship
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control group with reflective diaries but no formal training
Number of subjects: 157
Study: 26852726

Group type: EXPERIMENTAL
Intervention: Oral solithromycin (800 mg on day 1, 400 mg on days 2-5, placebo on days 6-7)
Number of subjects: 860

Group type: COMPARATOR
Intervention: Oral moxifloxacin (400 mg on days 1-7)
Number of subjects: 860

Group type: EXPERIMENTAL
Intervention: Oral solithromycin
Number of subjects: 860

Group type: COMPARATOR
Intervention: Oral moxifloxacin
Number of subjects: 860
Study: 24664567

Group type: EXPERIMENTAL
Intervention: 100% CO2
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 50:50 CO2:argon
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (ambient air)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Faster flow rates
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Slower flow rates
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Neonate pigs
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Weaned pigs
Number of subjects: 20
Study: 22760574

Group type: EXPERIMENTAL
Intervention: Short sleep (SS; 4 h/night)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Long sleep (LS; 9 h/night)
Number of subjects: 21
Study: 20929552

Group type: EXPERIMENTAL
Intervention: Labral repair
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Biceps tenodesis
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (diagnostic arthroscopy)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 120
Study: 17908897

Group type: EXPERIMENTAL
Intervention: Cementless tibial fixation with hydroxyapatite
Number of subjects: 81

Group type: COMPARATOR
Intervention: Cemented tibial fixation
Number of subjects: 81
Study: 16208714

Group type: EXPERIMENTAL
Intervention: 6 Fr guiding catheter
Number of subjects: 414

Group type: COMPARATOR
Intervention: 7 Fr guiding catheter
Number of subjects: 414
Study: 11834844

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No Hormone Replacement Therapy (Control)
Number of subjects: 50
Study: 10445371

Group type: EXPERIMENTAL
Intervention: Zaleplon (25, 50, and 75 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Triazolam (0.25, 0.5, and 0.75 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Zaleplon and Triazolam
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Zaleplon
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 1541953

Group type: EXPERIMENTAL
Intervention: 1800 degrees rotation of the Cervex-Brush
Number of subjects: 516

Group type: COMPARATOR
Intervention: 180 degrees rotation of the Cervex-Brush
Number of subjects: 516

Group type: COMPARATOR
Intervention: 360 degrees rotation of the Cervex-Brush
Number of subjects: 516

Group type: COMPARATOR
Intervention: 720 degrees rotation of the Cervex-Brush
Number of subjects: 516

Group type: COMPARATOR
Intervention: 1080 degrees rotation of the Cervex-Brush
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Overall results
Number of subjects: 516
Study: 4040553

Group type: EXPERIMENTAL
Intervention: Dexamethasone (20 mg IV, two hours before and 3, 6, 9, and 12 hours after chemotherapy)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Dexamethasone after crossover from placebo
Number of subjects: 64
Study: 30928952

Group type: EXPERIMENTAL
Intervention: Videotaped observation by a clinical child psychologist or child psychiatrist and a study nurse followed by interactive video guidance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Videotaped observation and interactive video guidance
Number of subjects: 0
Study: 29746955

Group type: EXPERIMENTAL
Intervention: Micafungin 100 mg intravenously daily
Number of subjects: 113

Group type: COMPARATOR
Intervention: Posaconazole suspension 400 mg orally twice daily
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Micafungin
Number of subjects: 113

Group type: COMPARATOR
Intervention: Posaconazole
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 113
Study: 26953867

Group type: EXPERIMENTAL
Intervention: Video game-based cognitive rehabilitation program
Number of subjects: 24

Group type: COMPARATOR
Intervention: Wait-list group (control)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study: 26137843

Group type: EXPERIMENTAL
Intervention: Peer-led social marketing intervention (Som la Pera) involving 5 Adolescent Challenge Creators (ACCs) who received 4 hours of training and 24 sessions (1.5 hours each) over 2 academic years.
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Peer-led social marketing intervention (Som la Pera) involving 5 Adolescent Challenge Creators (ACCs).
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group with no intervention implemented.
Number of subjects: 240
Study: 23516998

Group type: EXPERIMENTAL
Intervention: Weight loss goal among nonsmokers
Number of subjects: 1592

Group type: EXPERIMENTAL
Intervention: Weight loss goal among former smokers
Number of subjects: 1592

Group type: EXPERIMENTAL
Intervention: Weight loss goal among smokers
Number of subjects: 1592
Study: 21518127

Group type: EXPERIMENTAL
Intervention: 20 IU oxytocin dissolved in 30 mL saline (n=26)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Ergometrine 0.2 mg dissolved in 30 mL saline (n=27)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Misoprostol 800 µg dissolved in 30 mL saline (n=25)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 78
Study: 18285698

Group type: COMPARATOR
Intervention: F8 HPS (low-flux) dialyzer (Group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: FX80 (high-flux) dialyzer (Group B)
Number of subjects: 40
Study: 17086737

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg of oral midazolam 20 minutes prior to dental treatment
Number of subjects: 40
Study: 12964680

Group type: EXPERIMENTAL
Intervention: MPDS‐SL
Number of subjects: 20

Group type: COMPARATOR
Intervention: Molloplast‐B
Number of subjects: 20
Study: 10999232

Group type: EXPERIMENTAL
Intervention: Ritalin
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 9624295

Group type: EXPERIMENTAL
Intervention: Budesonide (800 micrograms via Turbohaler)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (identical to budesonide)
Number of subjects: 15
Study: 7937971

Group type: EXPERIMENTAL
Intervention: Parachute jumping (intervention group, n = 26)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (not jumping, n = 17)
Number of subjects: 43
Study: 3064641

Group type: EXPERIMENTAL
Intervention: Bedtime ethanol (2 ml/kg of 100 proof vodka mixed in orange juice)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (1-2 drops of vodka floated on top of the orange juice)
Number of subjects: 6
Study: 29761006

Group type: EXPERIMENTAL
Intervention: Intravenous sodium valproate, 30 mg/kg as loading dose and then 4-8 mg/kg every 8 hr as maintenance regimen
Number of subjects: 110

Group type: COMPARATOR
Intervention: Intravenous phenytoin (IV PHT) 20 mg/kg as loading dose and then 1.5 mg/kg for 8 hr as maintenance therapy
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Both groups (sodium valproate and phenytoin)
Number of subjects: 110
Study: 28107596

Group type: EXPERIMENTAL
Intervention: Reduced nicotine content (RNC) cigarettes (stepdown and non-stepdown groups)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Preferred brand (control group)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Non-stepdown RNC cigarette groups
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Transition from preferred to lowest RNC cigarettes
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Transition from highest to lowest RNC cigarettes
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: More favorable initial taste ratings of study cigarettes
Number of subjects: 246
Study: 25692315

Group type: EXPERIMENTAL
Intervention: Iron supplementation (B1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (B2)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both iron and folic acid supplementation (B3)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: No supplementation (B4)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (non-pregnant healthy women)
Number of subjects: 50
Study: 22963271

Group type: EXPERIMENTAL
Intervention: Homeopathic combination remedy dysto-loges S
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40